Intellia Therapeutics, Inc.

NASDAQ:NTLA

Biotechnology

Healthcare
$9.52 +0.14%

+$0.02 today

Market cap
$1.34B
Beta
1.81
P/E (TTM)
-4.6
EPS (TTM)
-$3.33
52W Low $7.95High $28.25

Volume 9.96M

Average 6.11M

Returns on capital

Intellia Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-61.5%

avg -34.5%

ROIC

-57.7%

avg -30.9%

ROA

-49.0%

avg -27.2%

Analysis

ROA is currently the strongest return metric at -49.0% versus its period average of -27.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Erik J. Sontheimer

Founder and Member of Scientific Advisor BoardUSD 1.38M———

Luciano Marraffini

Founder and Member of Scientific Advisor BoardUSD 1.38M———

Derrick J. Rossi

Founder and Member of Scientific Advisor BoardUSD 1.38M———

Rodolphe Barrangou

Founder and Member of Scientific Advisor BoardUSD 1.38M———

Jennifer A. Doudna

Founder and Member of Scientific Advisor BoardUSD 1.38M62——

John Leonard

President, Chief Executive Officer & DirectorUSD 1.26M69——

Edward J. Dulac

Executive Vice President, Chief Financial Officer and TreasurerUSD 853.71K51——

James E. Basta

Executive Vice President, General Counsel & Corporate SecretaryUSD 732.37K60——

Birgit Schultes

Executive VP & Chief Scientific OfficerUSD 708.86K63——

Michael Dube

VP & Chief Accounting OfficerUSD 478.49K48——

Rachel E. Haurwitz

Co-Founder—400<0.01%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 11, 2016.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$1.40M

Sells

19

$2.27M

Net Transaction Value

−$868,724.46

Net selling

Most Active

LEONARD JOHN M

7 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 2, 26

LEONARD JOHN M

Direct

Sell$107.9K
Oct 2, 26

Dube Michael P

Direct

Sell$23.2K
Aug 21, 26

LEONARD JOHN M

Direct

Sell$36.2K
Aug 20, 26

LEONARD JOHN M

Direct

Sell$250.6K
Jul 22, 26

Dulac Edward J III

Direct

Sell$91.2K
Jul 2, 26

Dulac Edward J III

Direct

Sell$84.2K
Jul 1, 26

Dube Michael P

Direct

Sell$44.3K
Mar 2, 26

BASTA JAMES

Direct

Sell$16.7K
Mar 2, 26

Clark Eliana

Direct

Sell$8.4K
Jan 5, 26

LEONARD JOHN M

Direct

Sell$314.5K

1–10 of 20

Summary

Insiders reported 1 buys worth $1.40M and 19 sells worth $2.27M over the last 12 months. That adds up to net selling of $868,724.46. LEONARD JOHN M was the most active insider with 7 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/A+9.1%
+92.2% (5yr)6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Recent growth has been strongest in Revenue at +9.1% over three years. Forward estimates point to Revenue at +92.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Intellia Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about NTLA's management, answered from reported figures.

Who manages NTLA?

Intellia Therapeutics, Inc. (NTLA) lists 11 active executives. The top listed executive is John Leonard, President, Chief Executive Officer & Director.

Are NTLA insiders buying or selling?

Recent insider activity shows net buying of $36.48M.